Other lipid agents × lipids

TrialEuropean heart journal2015

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.

Christopher P Cannon et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 720 people · 2015

No range given

Reported higher lipids, no range given

+2.30percentage points

As reported

difference 2.3 %, no interval

One number in the abstract

the abstract, start to end

± 1.9% for ezetimibe (difference 29.8 ± 2.3%; P < 0.0001); 77.0% of

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Lipids
2.3
PCSK9 inhibitorsOther lipid agentsLipids
1 / 3

166 papers cite itlatest 60 shown

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

3 trials

Full record →Abstract, authors, funding and every citing paper · PMID 25687353